Citation

  • Authors: Murauer, E. M., Koller, U., Hainzl, S., Wally, V., Bauer, J. W.
  • Year: 2013
  • Journal: Hum Gene Ther Methods 24 19-27
  • Applications: in vitro / DNA / jetPEI
  • Cell types:
    1. Name: AD-293
    2. Name: Phoenix
      Description: Human embryonic kidney Fibroblast transformed with adenovirus E1a. Available through Orbigen.

Abstract

In the treatment of genetic disorders, repairing defective pre-mRNAs by RNA trans-splicing has become an emerging alternative to conventional gene therapy. Previous studies have made clear that the design of the binding domains of the corrective RNA trans-splicing molecules (RTMs) is crucial for their optimal functionality. We established a reporter-based screening method that allows for selection of highly functional RTMs from a large pool of variants. The efficiency and functionality of the screen were validated in the COL7A1 gene, in which mutations are the cause of the skin disease dystrophic epidermolysis bullosa. Comparison of RTMs containing different binding domains hybridizing to COL7A1 intron 64/exon 65 revealed highly different trans-splicing efficiencies. Isolated RTMs were then adapted for endogenous trans-splicing in a recessive dystrophic epidermolysis bullosa (RDEB) keratinocyte cell line expressing reduced levels of COL7A1 mRNA. Our results confirm the applicability and relevance of prescreening reporter RTMs, as significant levels of endogenous COL7A1 mRNA repair were seen with RTMs identified as being highly efficient in our screening system.

Go to